Analysis of the pan-Asian subgroup of patients in the NALA Trial: a randomized phase III NALA Trial comparing neratinib+capecitabine (N+C) vs lapatinib+capecitabine (L+C) in patients with HER2+metastatic breast cancer (mBC) previously treated with two or more HER2-directed regimens.
Ming Shen DaiYin Hsun FengShang Wen ChenNorikazu MasudaThomas YauShou Tung ChenYen Shen LuYoon Sim YapPeter C S AngSung Chao ChuAva KwongKeun Seok LeeSamuel OwSung Bae KimJohnson LinHyun Cheol ChungRoger NganVictor C KokKun Ming RauTakafumi SangaiTing Ying NgLing Ming TsengRichard BryceJudith BebchukMei Chieh ChenMing-Feng HouPublished in: Breast cancer research and treatment (2021)
NCT01808573.
Keyphrases
- phase iii
- metastatic breast cancer
- open label
- clinical trial
- phase ii
- end stage renal disease
- double blind
- newly diagnosed
- placebo controlled
- chronic kidney disease
- ejection fraction
- prognostic factors
- peritoneal dialysis
- study protocol
- squamous cell carcinoma
- radiation therapy
- patient reported outcomes
- rectal cancer